Clinical Efficacy of Multi-Focal Low-Intensity Extracorporeal Shockwave Therapy in the Treatment of Chronic Prostatitis/Chronic Pelvic Pain Syndrome: Prospective-Randomized, Double Blind, Placebo-Controlled Study

PurposeTo assess the safety and effect of the multifocal low-intensity extracorporeal shockwave therapy (MESWT) in the treatment of chronic prostatitis/chronic pelvic pain syndrome (CP/CPPS).Materials and MethodsWe randomly separated 30 patients with CP/CPPS into a MESWT and placebo group of same nu...

Full description

Saved in:
Bibliographic Details
Published in:The world journal of men's health 2022-10, Vol.40 (4), p.678-685
Main Authors: Kim, Kang Sup, Choi, Yong Sun, Bae, Woong Jin, Cho, Hyuk Jin, Ha, U-Syn, Hong, Sung-Hoo, Lee, Ji Youl, Han, Chang Hee, Kim, Sae Woong
Format: Article
Language:English
Subjects:
Antibiotics
chronic pelvic pain syndrome
Double-blind studies
Leukocytes
Lithotripsy
low-intensity extracorporeal shock wave therapy
multi-focal
Original
Pain
Penis
Prostate
Questionnaires
Statistical analysis
Urine
Urogenital system
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:PurposeTo assess the safety and effect of the multifocal low-intensity extracorporeal shockwave therapy (MESWT) in the treatment of chronic prostatitis/chronic pelvic pain syndrome (CP/CPPS).Materials and MethodsWe randomly separated 30 patients with CP/CPPS into a MESWT and placebo group of same number using prospective-randomized, double-blind design. The participants' National Institutes of Health Chronic Prostatitis Symptom Index (NIH-CPSI) total and subdomain scores, International Prostate Symptom Score (IPSS), International Index of Erectile Function-5 (IIEF-5), and visual analogue scale (VAS) were assessed and compared at baseline and at finishing immediately and 4 weeks after procedure and also were compared between MESWT and placebo group.ResultsA total of 30 participants were randomized a MESWT or placebo group. Twenty of thirty participants completed this trial. NIH-CPSI total and subdomain scores, IPSS, IIEF-5, and VAS had significantly ameliorated compared with baseline in the MESWT group at 4 weeks assessment. Furthermore, comparison of the results from MESWT and placebo groups represented statistically significant differences in NIH-CPSI total and subdomain scores, IPSS, IIEF-5, and VAS. No side effects or events were occurred in both groups of the participants during study periods.ConclusionsMESWT can be an effective treatment modality in patients with CP/CPPS as it improves pain and QoL.
ISSN:2287-4208
2287-4690
DOI:10.5534/wjmh.210078